GlassScriptPhysician profile
Stephen B Trammell
NPI 1922004886
$4,220.08
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $1,233 · 2021: $1,011 · 2022: $949 · 2023: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $691.36 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $662.42 | 2019-2022 | |
| Novo Nordisk INC | $450.02 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.95 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $300.45 | 2019-2023 | |
| Glaxosmithkline, LLC. | $262.20 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $189.53 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.53 | 2022 | |
| Lilly USA, LLC | $113.06 | 2020-2023 | Mounjaro |
| Eisai INC. | $107.84 | 2020-2021 | |
| Antares Pharma, INC. | $105.19 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Kowa Pharmaceuticals America, INC. | $102.53 | 2019-2023 | Seglentis, Livalo |
| Abbvie INC. | $101.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.16 | 2020-2022 | |
| Allergan, INC. | $55.44 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $46.11 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $38.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.68 | 2019 | |
| Dexcom, INC. | $35.18 | 2021-2022 | |
| Aytu Biopharma, INC. | $34.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.34 | 2020-2021 | |
| Corcept Therapeutics | $23.16 | 2023 | Korlym |
| Exact Sciences Corporation | $21.66 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $19.48 | 2021 | |
| Edwards Lifesciences Corporation | $19.38 | 2022 | |
| Assertio Therapeutics, INC. | $19.03 | 2020 | |
| Tanabe Pharma America, INC. | $18.45 | 2022 | |
| Amgen INC. | $18.15 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.05 | 2021 | |
| Daiichi Sankyo INC. | $15.85 | 2021 | |
| Althera Pharmaceuticals LLC | $15.69 | 2021 | |
| Genentech USA, INC. | $15.32 | 2021 | |
| Metuchen Pharmaceuticals | $14.21 | 2020 | |
| Abbott Laboratories | $12.50 | 2022 | |
| Angiodynamics, INC. | $12.40 | 2021 | |
| Vistapharm, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Trammell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.